Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

EPS
WisdomTree U.S. LargeCap Fund
stock NYSE ETF

Market Open
9/21/2023 2:12:30 PM EDT
46.59USD-0.809%(-0.38)8,557
0.00Bid   0.00Ask   0.00Spread IEX
Pre-market
1969-12-31
0.00USD-100.000%(-46.97)0
After-hours
1969-12-31
0.00USD0.000%(0.00)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsTrends
EPS Reddit Mentions
Subreddits
Limit Labels     

We have sentiment values and mention counts going back to 2017. The complete data set will be available via the API.
Notify me when the API is ready
EPS Specific Mentions
As of Sep 21, 2023 2:24:16 PM EDT (<1 min. ago)
Includes all comments and posts. Mentions per user per ticker capped at one per hour.
1 hr ago • u/Scarneck • r/stocks • full_analysis_of_amneal_amrx • Company Discussion • B

**BLUF**: Amneal Pharmaceuticals (AMRX) is a pharmaceutical company that is poised for a significant upside following a slew of new drugs approved by both the FDA and China. I wanted to share my bullish thesis on why AMRX looks like a strong investment opportunity right now.
I want to disclose that I remain fully convinced this stock will continue appreciating in value, even after making a significant amount of money form it so far. I purchased 2,500 shares on April 19 at $1.62 per share (166% gain) and 546 contracts (x100) of the Dec 15 '23 $5 calls, which are now worth 0.45 per contracts (128% gain).
So how did I know Amneal was primed to pop? Huge credit goes to my girlfriend - she's a nurse practitioner and tipped me off in April about a drug that was being discontinued by one of Amneal's competitors (this is all public info if you know where to look). This piqued my interest, so I started analyzing Amneal as the company likely to ramp up production of that drug.
Right away, I noticed strange after-hours price action - the stock would jump 10% during the day, then shed 8% after hours. Upon closer inspection, it became clear someone was buying up discounted shares after-hours as the price incrementally crept higher.
**Known Drugs that are popping:**
Colestipol: Colestipol is used with diet adjustments to reduce 'bad cholesterol' in people with high cholesterol. It belongs to a group of medications called bile acid sequestrants and works by binding bile acids in the intestines, which are then removed from the body.
Vyvanse: Some of you are probably aware that ADHD drugs are in high demand right now and that there’s a shortage, well Amneal received approval for the generic drug.
Now, onto the fundamentals:
**Business Overview:**
* Fully integrated pharma company focused on generics, specialty drugs, and government distribution. 4th largest generics maker in the U.S.
* A diversified portfolio of \~270 complex products like injectables, inhalants, and topicals.
* Growing specialty segment targeting CNS and endocrine disorders.
* AvKARE acquisition expanded presence in government channels.
**Recent Catalysts:**
* Q2 beat on revenue ($599M, +7% YoY) and EPS ($0.19).
* Launched authorized generic of Xyrem - key new complex product.
* Got FDA approval for 5 complex generics, including 3 injectables. On track for 30+ launches in 2023.
* Continued biosimilars momentum with 3rd launch, FYLNETRA.
* Submitted ANDAs for 3 more high-value complex products.
* Raised full-year guidance on revenue, EBITDA, and EPS due to robust performance.
**Growth Drivers:**
* Deep pipeline of pending ANDA approvals for complex generics and biosimilars.
* More authorized generics partnerships like Xyrem.
* Expanding injectables and biosimilars into higher-value products.
* Continued government distribution penetration via AvKARE.
* International expansion is underway in China and Canada.
**Financials**:
* Solid revenue growth - new 2023 guidance of $2.3B-$2.4B (+11% YoY at midpoint).
* Expanding EBITDA margins, with 2023 EBITDA of $525M-$540M (+18% YoY at midpoint).
* EPS growth from operating leverage. 2023 EPS guidance raised to $0.45-$0.55 (+29% YoY at midpoint).
* Strong cash flow to fund growth and potential shareholder returns.
**Valuation**:
* Trades at just 7x 2023 EPS guidance midpoint of $0.50. Very reasonable given expected growth.
* EV/EBITDA of 5.5x on 2023 guidance midpoint of $532.5M is a discount to peers.
Institutional Movements:
Several institutional investors adjusted their holdings in AMRX during Q1:
* Swiss National Bank increased its shares by 8.6%.
* Bank of New York Mellon Corp increased its stake by 1.1%.
* MetLife Investment Management LLC grew its position by a notable 169.4%.
* Panagora Asset Management Inc. raised its stake by 109.5%.
* BlackRock Inc., a major player, increased its position by 1.3%.
* Collectively, institutional investors and hedge funds own about 31.82% of the company.
**Stock Performance:**
* AMRX's shares started at $4.32 on a recent Wednesday, with a recent trend above their average: 50-day average is $3.75 and 200-day average is $2.68.
* Over the past year, the stock ranged from a low of $1.24 to a high of $4.74.
* The company's market cap stands at $1.32 billion, and its stock metrics include a PE ratio of -216.00 and a beta of 1.31.
* Financial ratios include a debt-to-equity of 17.18 and liquidity ratios of 1.12 (quick) and 1.83 (current).
**Good Vs. Bad:**
Positive Signs:
* Insider Ownership: A significant portion of the company's stock (26.56%) is owned by company insiders. This is typically viewed as a vote of confidence from those who understand the company best.
* Institutional Interest: Various reputable institutional investors have increased their stake in the company, which could indicate a positive sentiment among major players
* Performance Metrics: The company beat its earnings estimates and posted higher revenues than expected in its recent quarterly earnings, which is a bullish sign.
* Strong Return on Equity: Despite a negative net margin, the company has a robust return on equity of 101.26%.
Concerns:
* High Debt-to-Equity Ratio: A ratio of 17.18 suggests that the company is heavily leveraged and may have significant interest payments.
* Negative PE Ratio: The negative PE ratio indicates the company is not profitable from an earnings perspective, which might be a concern for some investors.
* Stock Volatility: A beta of 1.31 suggests that the stock is more volatile than the market. This might lead to more significant price swings.
**TLDR**: Amneal is an undervalued, high-growth pharma play with multiple near and long-term catalysts, due to it’s fundamentals and new drugs. The disconnect between strong fundamentals and low valuation multiples positions the stock for a breakout.
Positions: 2,500 shares of AMRX546 Dec 15 '23 $5 Call
sentiment 1.00
2 hr ago • u/Scarneck • r/wallstreetbets • winter_is_coming_and_so_is_amrx • DD • B
**BLUF**: Amneal Pharmaceuticals (AMRX) is a pharmaceutical company that is poised for a significant upside following a slew of new drugs approved by both the FDA and China. I wanted to share my bullish thesis on why AMRX looks like a strong investment opportunity right now.
I want to disclose that I remain fully convinced this stock will continue appreciating in value, even after making a significant amount of money form it so far. I purchased 2,500 shares on April 19 at $1.62 per share (166% gain) and 546 contracts (x100) of the Dec 15 '23 $5 calls, which are now worth 0.45 per contracts (128% gain).
So how did I know Amneal was primed to pop? Huge credit goes to my girlfriend - she's a nurse practitioner and tipped me off in April about a drug that was being discontinued by one of Amneal's competitors (this is all public info if you know where to look). This piqued my interest, so I started analyzing Amneal as the company likely to ramp up production of that drug.
Right away, I noticed strange after-hours price action - the stock would jump 10% during the day, then shed 8% after hours. Upon closer inspection, it became clear someone was buying up discounted shares after-hours as the price incrementally crept higher.
**Known Drugs that are popping:**
Colestipol:  Colestipol is used with diet adjustments to reduce 'bad cholesterol' in people with high cholesterol. It belongs to a group of medications called bile acid sequestrants and works by binding bile acids in the intestines, which are then removed from the body. 
Vyvanse: All of you regards should know that ADHD drugs are in high demand right now and that there’s a shortage (probably because it’s cheaper than coke), well Amneal received approval for the generic drug so that all of you can go back to your ADHD supply. 
Now, onto the boring stuff…fundamentals:
**Business Overview:**
* Fully integrated pharma company focused on generics, specialty drugs, and government distribution. **4th largest generics maker in the U.S.**
* A diversified portfolio of \~270 complex products like injectables, inhalants, and topicals.
* Growing specialty segment targeting CNS and endocrine disorders.
* AvKARE acquisition expanded presence in government channels.
**Recent Catalysts:**
* Q2 beat on revenue ($599M, +7% YoY) and EPS ($0.19).
* Launched authorized generic of Xyrem - key new complex product.
* Got FDA approval for 5 complex generics, including 3 injectables. On track for 30+ launches in 2023.
* Continued biosimilars momentum with 3rd launch, FYLNETRA.
* Submitted ANDAs for 3 more high-value complex products.
* Raised full-year guidance on revenue, EBITDA, and EPS due to robust performance.
**Growth Drivers:**
* Deep pipeline of pending ANDA approvals for complex generics and biosimilars.
* More authorized generics partnerships like Xyrem.
* Expanding injectables and biosimilars into higher-value products.
* Continued government distribution penetration via AvKARE.
* International expansion is underway in China and Canada.
**Financials:**
* Solid revenue growth - new 2023 guidance of $2.3B-$2.4B (+11% YoY at midpoint).
* Expanding EBITDA margins, with 2023 EBITDA of $525M-$540M (+18% YoY at midpoint).
* EPS growth from operating leverage. 2023 EPS guidance raised to $0.45-$0.55 (+29% YoY at midpoint).
* Strong cash flow to fund growth and potential shareholder returns.
**Valuation**:
* Trades at just 7x 2023 EPS guidance midpoint of $0.50. Very reasonable given expected growth.
* EV/EBITDA of 5.5x on 2023 guidance midpoint of $532.5M is a discount to peers.
**Institutional Movements:**
* Several institutional investors adjusted their holdings in AMRX during Q1:
* Swiss National Bank increased its shares by 8.6%.
* Bank of New York Mellon Corp increased its stake by 1.1%.
* MetLife Investment Management LLC grew its position by a notable 169.4%.
* Panagora Asset Management Inc. raised its stake by 109.5%.
* BlackRock Inc., a major player, increased its position by 1.3%.
* Collectively, institutional investors and hedge funds own about 31.82% of the company.
**Stock Performance:**
* AMRX's shares started at $4.32 on a recent Wednesday, with a recent trend above their average: 50-day average is $3.75 and 200-day average is $2.68.
* Over the past year, the stock ranged from a low of $1.24 to a high of $4.74.
* The company's market cap stands at $1.32 billion, and its stock metrics include a PE ratio of -216.00 and a beta of 1.31.
* Financial ratios include a debt-to-equity of 17.18 and liquidity ratios of 1.12 (quick) and 1.83 (current).
**Good Vs. Bad:**
Positive Signs:
Insider Ownership: A significant portion of the company's stock (26.56%) is owned by company insiders. This is typically viewed as a vote of confidence from those who understand the company best.
Institutional Interest: Various reputable institutional investors have increased their stake in the company, which could indicate a positive sentiment among major players.
Performance Metrics: The company beat its earnings estimates and posted higher revenues than expected in its recent quarterly earnings, which is a bullish sign.
Strong Return on Equity: Despite a negative net margin, the company has a robust return on equity of 101.26%.
Concerns:
High Debt-to-Equity Ratio: A ratio of 17.18 suggests that the company is heavily leveraged and may have significant interest payments.
Negative PE Ratio: The negative PE ratio indicates the company is not profitable from an earnings perspective, which might be a concern for some investors.
Stock Volatility: A beta of 1.31 suggests that the stock is more volatile than the market. This might lead to more significant price swings.
**TLDR**: Amneal is an undervalued, high-growth pharma play with multiple near and long-term catalysts, due to it’s fundamentals and new drugs. The disconnect between strong fundamentals and low valuation multiples positions the stock for a breakout. 
Positions: 2,500 shares of AMRX 546 Dec 15 '23 $5 Call
sentiment 1.00
2 hr ago • u/Samwhys_gamgee • r/FluentInFinance • is_this_due_to_inflation_or_corporate_greed • C
True about EPS, but margins (and debt) will influence the PE ratio the street will value a company at, so it does have an impact. I bought CAG a while back after a dip and despite good eps growth thru Covid, they can’t break 40 because of lower margins then their peer set. They are actually below their March 2020 price now despite big eps and sales growth.
sentiment -0.55
2 hr ago • u/ListerineInMyPeehole • r/wallstreetbets • daily_discussion_thread_for_september_21_2023 • C
I believe at around \~400 early in 2023, SPY EPS was forecasted to be flattish to slightly down YoY
sentiment 0.01
3 hr ago • u/PepperBeeMan • r/wallstreetbets • dollar_general_is_in_a_really_bad_situation_and • C
They have missed EPS estimates for last year nearly every quarter, but revenue is up 37% since 2020.
sentiment -0.06
4 hr ago • u/woodsman775 • r/amcstock • they_short_everything • Why I Hold 🦍💙 • B
I watch several stocks and 2 that I’m also invested in besides AMC. Plug Power and Rivian.
Both up and coming companies, Rivian EPS and other metrics for them are improving, quickly. Plug power is like the NVIDIA of hydrogen fuel companies, and is poised to dominate the industry when hydrogen fuel becomes huge…and it will…cheap and almost 0 carbon footprint. It will be able to run substations, semis, trains…the tech has come a long way.
My point is, when you pull up a lot of companies short interest, most are around 3-5%, look at ones I’m watching such as the 2 I mentioned…plug 23% Rivian 14%. If you keep digging, several companies are being shorted near 20%. That being said, I kinda think if one pops, they lose control of their ENTIRE short portfolio. Explains a lot about why companies can’t recover very well from a down turn and the public’s portfolios get robbed.
sentiment 0.69
6 hr ago • u/Personal_Fig42 • r/investing • why_tgls_is_a_golden_opportunity_and_will_bounce • B
Hi everyone, I want to share with you my analysis and opinion on TGLS, a stock that I think is undervalued and has huge upside potential. TGLS is Tecnoglass Inc., a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets.
## The company
Tecnoglass operates in the US, Colombia, and other Latin American countries. It has a strong competitive advantage in terms of quality, innovation, and cost efficiency. It has a diversified customer base, ranging from homebuilders, contractors, architects, and developers. It also has a strategic partnership with Saint-Gobain, one of the world's largest glass manufacturers.
## The financials
Tecnoglass has been growing steadily and profitably over the years. In the second quarter of 2023, it reported a revenue of $137.5 million, up 34% year-over-year, and an adjusted EBITDA of $40.3 million, up 50% year-over-year. It also beat the EPS estimates by $0.12 and raised its full-year guidance for revenue and adjusted EBITDA. It has a strong balance sheet, with a cash position of $97.9 million and a net debt to adjusted EBITDA ratio of 1.8x.
## The opportunity
Despite its impressive performance, TGLS is trading at a low valuation compared to its peers and the market. As of today, TGLS has a market cap of $1.67 billion and a PE ratio of 8.26, while the average PE ratio of its industry is 19.76 and the average PE ratio of the S&P 500 is 28.77. TGLS also has a dividend yield of 1.03%, which is higher than the average dividend yield of its industry (0.82%) and the S&P 500 (1.01%).
The reason why TGLS is undervalued is because the market is not efficient and has overlooked one important factor: the cash flow. In the second quarter of 2023, TGLS reported a negative operating cash flow of $15.4 million, which was mainly due to a one-time tax payment of $97 million. This tax payment was the result of a tax reform in Colombia that allowed TGLS to settle its deferred tax liabilities at a lower rate. This was a smart move by TGLS, as it reduced its future tax burden and increased its net income. However, the market did not appreciate this and focused on the negative cash flow instead.
This is a short-term issue that will be resolved in the next quarter, when TGLS will report a positive operating cash flow and a higher free cash flow. This will also enable TGLS to increase its dividend, reduce its debt, or invest in growth opportunities. Once the market realizes this, TGLS will be revalued and its stock price will rise accordingly.
## The conclusion
TGLS is a golden opportunity for investors who are looking for a high-quality, high-growth, and high-dividend stock at a bargain price. TGLS has a strong competitive advantage, a solid financial performance, and a bright future outlook. It is currently undervalued due to a temporary cash flow issue that will be resolved soon. I expect TGLS to bounce back and reach its fair value of at least $50 per share, which implies a 47% upside potential from the current price of $34 per share.
## The disclaimer
This post is not financial advice and I am not a financial advisor. I am just sharing my personal opinion and analysis on TGLS. You should do your own research and due diligence before investing in any stock. Investing involves risks and you may lose money.
sentiment 0.99
8 hr ago • u/_Kenway • r/wallstreetbets • what_are_your_moves_tomorrow_september_21_2023 • C
>showing monthly earnings
eps inflation adj, more relevant
but here's EPS chart from macrotrends
[https://imgur.com/a/B7Ekggl](https://imgur.com/a/B7Ekggl)
EPS were up approx +120% pre 73 bear market to 80, SPX was still flat on nominal and down a lot adjusted, idk where you are looking at
sentiment -0.48
9 hr ago • u/kevonlooneytunes • r/wallstreetbets • what_are_your_moves_tomorrow_september_21_2023 • C
I'm confused by this chat because it certainly is not showing monthly earnings. The values kind of align with annual earnings but still, how does it make sense to show 177.41 for March. Nonetheless, throughout the 1970s, when EPS is increasing so is SPX. That time period goes along with the old saying that markets bottom first, then earnings bottom, and then the economy.
Also, without a massive supply shock in 2024, I don't think 1970s stagflation is a good comparison.
sentiment 0.33
10 hr ago • u/kevonlooneytunes • r/wallstreetbets • what_are_your_moves_tomorrow_september_21_2023 • C
EPS was down in the years of the bottom the bear markets in 1968 crash and 1970 crash. I don't have granular QoQ data for those years but I think that tracks with SP 500 bottoming in Oct 2022 and EPS for that 2023 Q1 being the bottom in the main fight against inflation. Thus taking the 70s as an example, EPS up does mean SPX up.
Currency devaluation is reflected in reported earnings. When dollar is high, earnings from abroad are worth less dollars and that is reflected in the earnings since they are reported in dollars
sentiment -0.61
11 hr ago • u/_Kenway • r/wallstreetbets • what_are_your_moves_tomorrow_september_21_2023 • C
you forgot about one scenario
EPS up do not always mean SPX up, 70s stagflation is an example
EPS are in USD, currency devaluation >> higher EPS mean nothing
sentiment 0.06
11 hr ago • u/kevonlooneytunes • r/wallstreetbets • what_are_your_moves_tomorrow_september_21_2023 • C
Don't think economy can collapse when home prices (the major asset in America) can't crash because of lack of supply and number of ppl locked into 3%. Furthermore huge gov spending will keep earnings up and thus there won't be mass layoffs. Fed knows max on the 10yr is 5% before something breaks so they are probably actually right for once that there will only be max 1 rate hike left. I think they have settled on running a hot economy with high rates (for longer) particularly because they can't influence government spending. Thus the only "collapse" in the stock market I think will happen is a rerating of multiples to actually reflect 4.5 on the 10yr because we know the 5% rates on the 2 year will actually last for a couple years. 250 is consensus on EPS for SPX 2024 and 17x multiple looks like historically what we had when 10yr was 4.5% ([https://www.yardeni.com/pub/sp5peinflby.pdf](https://www.yardeni.com/pub/sp5peinflby.pdf))
If we take a lower estimate of 240 EPS for 2024 on SPX it's 4080 so that's what I think a very safe, fair value is so like we're not extremely overvalued. I think this lower estimate is a good fair value because like I said, I don't think the economy can collapse but it can certainly slow down in terms of consumer spending.
Don't forget, higher for longer means a hot economy which means earnings keep growing.
sentiment 0.89
13 hr ago • u/Personal_Fig42 • r/wallstreetbets • what_are_your_moves_tomorrow_september_21_2023 • C
Hi everyone, I want to share with you my analysis and opinion on TGLS, a stock that I think is undervalued and has huge upside potential. TGLS is Tecnoglass Inc., a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets.
## The company
Tecnoglass operates in the US, Colombia, and other Latin American countries. It has a strong competitive advantage in terms of quality, innovation, and cost efficiency. It has a diversified customer base, ranging from homebuilders, contractors, architects, and developers. It also has a strategic partnership with Saint-Gobain, one of the world's largest glass manufacturers.
## The financials
Tecnoglass has been growing steadily and profitably over the years. In the second quarter of 2023, it reported a revenue of $137.5 million, up 34% year-over-year, and an adjusted EBITDA of $40.3 million, up 50% year-over-year. It also beat the EPS estimates by $0.12 and raised its full-year guidance for revenue and adjusted EBITDA. It has a strong balance sheet, with a cash position of $97.9 million and a net debt to adjusted EBITDA ratio of 1.8x.
## The opportunity
Despite its impressive performance, TGLS is trading at a low valuation compared to its peers and the market. As of today, TGLS has a market cap of $1.67 billion and a PE ratio of 8.26, while the average PE ratio of its industry is 19.76 and the average PE ratio of the S&P 500 is 28.77. TGLS also has a dividend yield of 1.03%, which is higher than the average dividend yield of its industry (0.82%) and the S&P 500 (1.01%).
The reason why TGLS is undervalued is because the market is not efficient and has overlooked one important factor: the cash flow. In the second quarter of 2023, TGLS reported a negative operating cash flow of $15.4 million, which was mainly due to a one-time tax payment of $97 million. This tax payment was the result of a tax reform in Colombia that allowed TGLS to settle its deferred tax liabilities at a lower rate. This was a smart move by TGLS, as it reduced its future tax burden and increased its net income. However, the market did not appreciate this and focused on the negative cash flow instead.
This is a short-term issue that will be resolved in the next quarter, when TGLS will report a positive operating cash flow and a higher free cash flow. This will also enable TGLS to increase its dividend, reduce its debt, or invest in growth opportunities. Once the market realizes this, TGLS will be revalued and its stock price will rise accordingly.
## The conclusion
TGLS is a golden opportunity for investors who are looking for a high-quality, high-growth, and high-dividend stock at a bargain price. TGLS has a strong competitive advantage, a solid financial performance, and a bright future outlook. It is currently undervalued due to a temporary cash flow issue that will be resolved soon. I expect TGLS to bounce back and reach its fair value of at least $50 per share, which implies a 47% upside potential from the current price of $34 per share.
## The disclaimer
This post is not financial advice and I am not a financial advisor. I am just sharing my personal opinion and analysis on TGLS. You should do your own research and due diligence before investing in any stock. Investing involves risks and you may lose money.
## The call to action
If you liked this post, please upvote, comment, or share it with others. I would love to hear your thoughts and feedback on TGLS. Thank you for reading and happy investing!
sentiment 1.00
20 hr ago • u/blibblub • r/SecurityAnalysis • nic_colas_on_valuing_tesla • C
That was 6 mins of the biggest nonsense I’ve ever heard.
World GDP is $100T and autonomous driving is worth 5% of that. Based on what?? Next year estimated diluted EPS is not $5. That would imply tesla is going to make a net of $17B next year. They are barely going to do $12B this year.
This is perfect for the retail buyer who doesn’t know what this guy is talking about. I wish I could get those 6mins of my life back.
sentiment 0.71
21 hr ago • u/MFalcone19 • r/wallstreetbets • is_disney_worth_buying • C
Main thing with disney is it's margin. Before Covid, it was netting 22%...currently it's 3%. Sat on the sidelines watching the stock fall until it hit it's covid low. currently have 5% position with 83 cost basis. Disney+ is getting close to profitability, the $60 billion invest in parks is great considering that's where DIS makes most their profit, and I think Iger is right for the job. EPS projection for 2027 is over $9 a share, selling for less than 10 times 4 years from now so analysts think margins will improve. Risky play but could pay off well over the next 5 years.
sentiment 0.84
22 hr ago • u/Nemarus_Investor • r/stocks • your_stock_is_not_a_cult_you_can_sell_dont_make • C
>Ok so 4% of current revenue would yield like $0.76 EPS right?
Yup.
We can start with PE, that would give it a PE of 23, making it more expensive than something like Target or Best Buy.
We need to take growth into account though, so at 15% growth of earnings going forward that's a PEG of 1.53, whereas Target is 1.12. Lower is better.
It makes GME seem pretty expensive even in this optimistic scenario of perpetual 15% growth.
sentiment 0.97
22 hr ago • u/LightningShark • r/stocks • your_stock_is_not_a_cult_you_can_sell_dont_make • C
Ok so 4% of current revenue would yield like $0.76 EPS right? How do we get from that to a valuation given a 10% growth rate?
sentiment 0.77
1 day ago • u/Bads-R-Mads • r/stocks • your_stock_is_not_a_cult_you_can_sell_dont_make • C
>I mean you know the one I'm talking about. Just take a look at the last 3 quarterly reports and give your honest impression of the company turn around.
Ok I will.
Q4 was bad, the company is built on surviving on its Q4 surges to offset their annual losses in the slower quarters. It did not achieve that, they posted an annual loss of nearly 300m dollars.
For comparison in 2018 Gamestop posted a Q4 earnings of .51 EPS, Q4 2019 was .40, Q4 2020 .32.
Q4 2022 .16 EPS.
And they largely achieved this by cutting every corner they can, its not a way to any long term success.
Q1 and Q2 so far you have posted a total loss of 52m dollars. Thats with arguably some of the biggest releases for your company included in that window. Zelda specifically which is one of the few titles that will still sell a large portion of its copies as physical due to the nature of Nintendo consoles lack of internal storage and the ease of cartridge swaps. This also includes Hogwarts and Star Wars, two titles that should bring "non gamers" into the gaming market and thus likely looking to buy hardware and other accessories that Gamestop would benefit from.
All that said, still posting a loss of 50m so far.
And then as far a turn around goes, what turnaround? They are not doing anything and havent signaled to shareholders any plan to do anything for 3 years now. Xbox just had its internal documents leaked showing a very near future where consoles are entirely digital cutting Gamestop entirely out of the market. Software makes up nearly 40% of Gamestops revenue meaning a loss of a massive portion of their business to this transition in the next 3-5 years.
What exactly is their plan to combat that?
>To me it's a long term investment at this point.
Its priced higher than it ever was when it was profitable, its still losing hundreds of millions of dollars every single year and its revenue is continually shrinking. Its market is still on the path to obsoleting Gamestops entire business model and there appears to be no attempt by Gamestop to pivot and survive the transition.
What the hell are you seeing that I am not?
>If it was the original meme stock
Tesla is the original meme stock.
>I don't feel it is meme anymore
Why/ What the fuck has changed? They still give no guidance, its still way above its price when it was significantly more profitable, it still is losing hundreds of millions of dollars every year with no plan to change that. And the business model is still deader than dead given the current trajectory of the business it is involved with.
What are you seeing?
>I'm happy with my investment so far.
Your company is currently -52m for year, you are down -35% over the past year, down 78% since the squeeze and still falling.
What are you happy about beyond the cult beliefs convincing you of nonsense?
sentiment -0.96
1 day ago • u/AMC-Apes-Together • r/amcstock • get_ready_for_it • C
"looking positive" because WE pay attention. I saw some posts that show analysts are forecasting a -0.47 EPS even after we have a positive EPS last quarter.
Looks like if AMC has a big beat they may finally take notice. Who the fuck knows.
sentiment 0.70
1 day ago • u/OverweightFinancials • r/weedstocks • daily_discussion_thread_september_20_2023 • C
I use financial modeling prep APIs. Unfortunately they don’t have realtime OTC pricing, but they do have realtime TSX data. So I’m pulling the TSX prices and converting to USD. (Volume data and historical prices when you pull up the chart by clicking on the tickers are still from OTC). Not sure about the P/E and EPS, they don’t provide much details on the data but I would guess its from the latest quarter.
sentiment -0.42


Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC